Latest papers

A Decade of Vaccines: Integrating Immunology and Vaccinology for Rational Vaccine Design

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.

The likelihood of participation in clinical trials can be measured: the Clinical Research Involvement Scales.

Update on mucosal HIV vaccine vectors.

Cofactors that may influence vaccine responses.

Is developing an HIV-1 vaccine possible?

An effective HIV vaccine: A combination of humoral and cellular immunity?

Strategies for eliciting HIV-1 inhibitory antibodies.

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

New approaches to design HIV-1 T-cell vaccines.

Back to the future: covalent epitope-based HIV vaccine development.

Poxvirus vector-based HIV vaccines.

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

Novel adenovirus vector-based vaccines for HIV-1.

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Role of adjuvants in modeling the immune response.

Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.

The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.